A randomized, double-blind, double-dummy, placebo-controlled, three-period, incomplete block, crossover study, to a investigate the effect of 14 days repeat inhaled dosing with GSK256066 in mild/moderate asthmatic patients.

Trial Profile

A randomized, double-blind, double-dummy, placebo-controlled, three-period, incomplete block, crossover study, to a investigate the effect of 14 days repeat inhaled dosing with GSK256066 in mild/moderate asthmatic patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs GSK 256066 (Primary)
  • Indications Asthma
  • Focus Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 20 May 2009 Inclusion and exclusion criteria amended from NCT
    • 27 Oct 2008 Actual start date changed from Dec 2007 to Nov 2007 as reported by ClinicalTrials.gov.
    • 27 Oct 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top